In a report released today, Craig Bijou from Cantor Fitzgerald assigned a Buy rating to Cerus Corp (NASDAQ: CERS), with a price target of $7. The company’s shares opened today at $6.52, close to its 52-week high of $6.79.
“We rate CERS Overweight and have a 12-month price target of $7. CERS commercializes INTERCEPT, the only FDA-approved system for pathogen- inactivated (PI) blood components. We believe 2018 will be a pivotal year for the company as it seeks to penetrate the platelet transfusion market in key geographical regions (US and internationally), which we expect to drive double-digit revenue growth. Longer term, CERS is seeking regulatory approval in Europe and the US to use its INTERCEPT system to treat red cells, and this is a company-estimated $5B market.”
According to TipRanks.com, Bijou is a 4-star analyst with an average return of 25.8% and a 70.8% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and Wright Medical Group.
Cerus Corp has an analyst consensus of Moderate Buy, with a price target consensus of $7.
The company has a one-year high of $6.79 and a one-year low of $1.93. Currently, Cerus Corp has an average volume of 1.12M.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Kevin Dennis Green, the CFO of CERS sold 73,000 shares for a total of $468,549.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.